Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with D
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | ENDOSINUSIAL | IMPLANT | 1.35 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | INTRAVITREAL | IMPLANT | 116.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | INTRAVITREAL | INJECTION | 116.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 12000 ACID | SUBCUTANEOUS | INJECTION, SOLUTION | 533.00 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | SUBCUTANEOUS | INJECTION, SUSPENSION, EXTENDED RELEASE | 37mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | INTRAMUSCULAR | INJECTION | 60.70 mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (50:50) COPOLYMER 63000 ACID | SUBCUTANEOUS | IMPLANT | 16mg | Correction | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (75:25) COPOLYMER 20000 ACID | INTRAMUSCULAR | INJECTION | 145mg | Correction | ||
| Q4 2022 | D&C YELLOW NO. 10 | ORAL | SUSPENSION/ DROPS | NA | Deletion | ||
| Q4 2022 | DISTEAROYLPHOSPHATIDYLCHOLINE, DL- | INTRAVENOUS | INJECTION | 0.68 %w/v | Deletion | ||
| Q3 2022 | D&C RED NO. 33 | ORAL | CAPSULE | 0.39 mg | MDE Replacement | ||
| Q4 2022 | D&C RED NO. 33 | ORAL | CAPSULE | 1mg | MDE Replacement | ||
| Q3 2022 | DIMETHYL SULFOXIDE | TOPICAL | SOLUTION | 45.50 %w/w | MDE Replacement | ||
| Q4 2022 | DIMETHYL SULFOXIDE | TOPICAL | SOLUTION | 3640mg | MDE Replacement | ||
| Q3 2022 | DYE GREEN LB-820 | ORAL | TABLET | 0.60 mg | MDE Replacement | ||
| Q4 2022 | DYE GREEN LB-820 | ORAL | TABLET | 2mg | MDE Replacement | ||
| Q4 2022 | DL-LACTIDE AND GLYCOLIDE (75:25) COPOLYMER 20000 ACID | INTRAMUSCULAR | INJECTION, POWDER, FOR SUSPENSION | 11mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: October 1, 2022
Database Last Updated: October 19, 2022